ATE551350T1 - Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration - Google Patents
Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegenerationInfo
- Publication number
- ATE551350T1 ATE551350T1 AT07812932T AT07812932T ATE551350T1 AT E551350 T1 ATE551350 T1 AT E551350T1 AT 07812932 T AT07812932 T AT 07812932T AT 07812932 T AT07812932 T AT 07812932T AT E551350 T1 ATE551350 T1 AT E551350T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- age
- cfhr
- macular degeneration
- related macular
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract 4
- 208000002780 macular degeneration Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000019553 vascular disease Diseases 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010002329 Aneurysm Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 210000003917 human chromosome Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83101806P | 2006-07-13 | 2006-07-13 | |
| US84007306P | 2006-08-23 | 2006-08-23 | |
| PCT/US2007/073514 WO2008008986A2 (en) | 2006-07-13 | 2007-07-13 | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551350T1 true ATE551350T1 (de) | 2012-04-15 |
Family
ID=38924245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07812932T ATE551350T1 (de) | 2006-07-13 | 2007-07-13 | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7867727B2 (de) |
| EP (3) | EP2447275B1 (de) |
| JP (1) | JP5431151B2 (de) |
| AT (1) | ATE551350T1 (de) |
| AU (1) | AU2007272335B2 (de) |
| CA (1) | CA2659392A1 (de) |
| DK (1) | DK2447275T3 (de) |
| IL (1) | IL196319A0 (de) |
| NZ (1) | NZ574046A (de) |
| SG (1) | SG173371A1 (de) |
| WO (1) | WO2008008986A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2597411C (en) * | 2005-02-14 | 2014-08-12 | University Of Iowa Research Foundation | Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration |
| US20080146501A1 (en) * | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| MX2009000909A (es) * | 2006-07-26 | 2009-02-04 | Univ Yale | Diagnostico y tratamiento de degeneracion macular relacionada con la edad. |
| US20100303832A1 (en) * | 2007-11-01 | 2010-12-02 | Hageman Gregory S | Genes and polymorphisms associated with amd |
| EP2238455A4 (de) * | 2008-01-18 | 2011-03-02 | Vatrix Medical Inc | Diagnostische biomarker für gefässaneurysma |
| DE102008049136B4 (de) * | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| KR20120049267A (ko) * | 2009-07-16 | 2012-05-16 | 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 | 치료 방법 |
| US20120190578A1 (en) * | 2009-08-06 | 2012-07-26 | Washington University | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes |
| JP2013504751A (ja) * | 2009-09-14 | 2013-02-07 | モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー | 血管疾患を診断および評価するためのポリペプチドマーカー |
| JP5706612B2 (ja) * | 2009-12-28 | 2015-04-22 | 学校法人 埼玉医科大学 | 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット |
| CA2814066A1 (en) * | 2010-10-14 | 2012-04-19 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| WO2012112955A2 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing iga nephropathy |
| CN103874526A (zh) * | 2011-04-29 | 2014-06-18 | 犹他大学研究基金会 | 预测补体介导的疾病的发展的方法 |
| JP2013064616A (ja) * | 2011-09-15 | 2013-04-11 | Osaka Univ | 高度動脈硬化を発症している可能性を検出する方法およびその利用 |
| WO2013150132A2 (de) * | 2012-04-05 | 2013-10-10 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| CN104995516A (zh) * | 2013-02-26 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 用于补体因子h相关蛋白质1检测的试剂、试剂盒和方法 |
| WO2014169294A1 (en) | 2013-04-12 | 2014-10-16 | The Trustees Of Columbia University In The City Of New York | Mutations in dstyk cause dominant urinary tract malformations |
| WO2014194213A1 (en) * | 2013-05-30 | 2014-12-04 | University Of Iowa Research Foundation | Specific complement proteins and efficacy of antibody therapy |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| WO2017109164A1 (en) | 2015-12-23 | 2017-06-29 | Université Pierre Et Marie Curie - Paris 6 (Upmc) | AGENTS THAT INHIBIT THE BINDING OF CFH TO CD11b/CD18 AND USES THEREOF |
| JP7537074B2 (ja) | 2016-05-10 | 2024-08-21 | ソルボンヌ ウニベルシテ | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| CA3100995A1 (en) * | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
| US20210338838A1 (en) | 2018-07-20 | 2021-11-04 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| DE102018120016B4 (de) | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
| WO2020180147A2 (ko) * | 2019-03-07 | 2020-09-10 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| CA3136119A1 (en) | 2019-04-10 | 2020-10-15 | University Of Utah Research Foundation | Htra1 modulation for treatment of amd |
| WO2021081203A1 (en) * | 2019-10-22 | 2021-04-29 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders |
| WO2022058447A1 (en) * | 2020-09-16 | 2022-03-24 | The University Of Manchester | Complementome assay |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5037746A (en) | 1986-12-03 | 1991-08-06 | University Patents, Inc. | RNA ribozyme polymerases, and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| DE68928853T2 (de) | 1988-05-20 | 1999-08-05 | Cetus Corp., Emeryville, Calif. | Befestigung von sequenzspezifischen proben |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| EP0512733A2 (de) | 1991-05-03 | 1992-11-11 | Washington University | Modifizierter Komplementsystemregler |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| ATE312188T1 (de) | 1993-01-22 | 2005-12-15 | Univ Research Corp | Lokalisierung von therapeutischen mitteln |
| US5667969A (en) | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| EP2305027B1 (de) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper |
| GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP2267138B1 (de) | 1998-04-08 | 2016-06-08 | Commonwealth Scientific and Industrial Research Organization | Verfahren und Mittel zum Erhalt von modifizierten Phänotypen |
| EP2314700A1 (de) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA |
| ATE343792T1 (de) | 1999-02-19 | 2006-11-15 | Univ Iowa Res Found | Diagnostika und therapeutika für maculare degeneration |
| US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| WO2001084149A2 (en) | 2000-04-29 | 2001-11-08 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
| KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| US7255858B2 (en) | 2001-08-10 | 2007-08-14 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
| BRPI0518289A2 (pt) * | 2004-11-18 | 2008-11-11 | Univ Yale | mÉtodos e composiÇÕes para o tratamento de desordens oculares |
| CA2597411C (en) | 2005-02-14 | 2014-08-12 | University Of Iowa Research Foundation | Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration |
| NZ565659A (en) | 2005-06-08 | 2010-03-26 | Univ Pittsburgh | Susceptibility genes for age-related maculopathy (ARM) on chromosome 10Q26 |
| CN101331235A (zh) | 2005-10-11 | 2008-12-24 | 耶鲁大学 | 与黄斑变性相关的基因 |
| US20080255000A1 (en) | 2005-11-02 | 2008-10-16 | Dogulu Cigdem F | Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd) |
| US20080146501A1 (en) | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
-
2007
- 2007-07-13 JP JP2009519713A patent/JP5431151B2/ja active Active
- 2007-07-13 AT AT07812932T patent/ATE551350T1/de active
- 2007-07-13 SG SG2011050705A patent/SG173371A1/en unknown
- 2007-07-13 CA CA002659392A patent/CA2659392A1/en not_active Abandoned
- 2007-07-13 DK DK12152177.7T patent/DK2447275T3/en active
- 2007-07-13 EP EP12152177.7A patent/EP2447275B1/de active Active
- 2007-07-13 WO PCT/US2007/073514 patent/WO2008008986A2/en not_active Ceased
- 2007-07-13 NZ NZ574046A patent/NZ574046A/xx not_active IP Right Cessation
- 2007-07-13 AU AU2007272335A patent/AU2007272335B2/en not_active Ceased
- 2007-07-13 EP EP07812932A patent/EP2046807B1/de active Active
- 2007-07-13 EP EP12152172.8A patent/EP2479284B1/de not_active Not-in-force
- 2007-08-20 US US11/894,667 patent/US7867727B2/en not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196319A patent/IL196319A0/en unknown
-
2010
- 2010-11-24 US US12/954,425 patent/US20120040884A1/en not_active Abandoned
-
2014
- 2014-05-15 US US14/279,235 patent/US20150050646A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/912,379 patent/US20180371547A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2447275T3 (en) | 2015-06-29 |
| EP2479284B1 (de) | 2017-09-20 |
| US20120040884A1 (en) | 2012-02-16 |
| US7867727B2 (en) | 2011-01-11 |
| US20180371547A1 (en) | 2018-12-27 |
| IL196319A0 (en) | 2009-09-22 |
| WO2008008986A3 (en) | 2008-10-23 |
| HK1168360A1 (en) | 2012-12-28 |
| EP2447275B1 (de) | 2015-04-01 |
| EP2447275A1 (de) | 2012-05-02 |
| JP2009544280A (ja) | 2009-12-17 |
| US20150050646A1 (en) | 2015-02-19 |
| WO2008008986A2 (en) | 2008-01-17 |
| HK1126223A1 (en) | 2009-08-28 |
| NZ574046A (en) | 2012-09-28 |
| EP2479284A2 (de) | 2012-07-25 |
| EP2046807B1 (de) | 2012-03-28 |
| EP2479284A3 (de) | 2012-08-08 |
| JP5431151B2 (ja) | 2014-03-05 |
| AU2007272335A1 (en) | 2008-01-17 |
| AU2007272335B2 (en) | 2014-03-27 |
| EP2046807A4 (de) | 2009-10-28 |
| US20080152659A1 (en) | 2008-06-26 |
| CA2659392A1 (en) | 2008-01-17 |
| SG173371A1 (en) | 2011-08-29 |
| EP2046807A2 (de) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551350T1 (de) | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration | |
| Houlden et al. | The phenotype of Charcot–Marie–Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy | |
| EP1766077A4 (de) | Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege | |
| IL183284A0 (en) | Methods and compositions for treating ocular disorders | |
| WO2006083533A3 (en) | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders | |
| NZ595305A (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
| CY1118902T1 (el) | Ρυθμιση της δραστικοτητας των προνευροτροφινων | |
| Gregson et al. | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date | |
| Tsang et al. | A novel mutation and phenotypes in phosphodiesterase 6 deficiency | |
| ATE371738T1 (de) | Mittel und verfahren zur diagnose und behandlung affektiver störungen | |
| DE602006002982D1 (de) | Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit | |
| Guo et al. | Whole-exome sequencing reveals a novel CHM gene mutation in a family with choroideremia initially diagnosed as retinitis pigmentosa | |
| WO2006096737A3 (en) | Diagnostic and therapeutic target for macular degeneration | |
| NO20073636L (no) | Sammensetninger og metoder til a behandle mentale lidelser | |
| WO2007059064A3 (en) | Fgf2-related methods for diagnosing and treating depression | |
| EP2005194A4 (de) | Auf hämoglobin basierende verfahren zur prophylaxe, diagnose bzw. behandlung von netzhauterkrankungen | |
| Foster et al. | Identification of an IGSF3 mutation in a family with congenital nasolacrimal duct obstruction. | |
| NO20070780L (no) | Celloverflateprotein. | |
| ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
| ATE394122T1 (de) | Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen | |
| WO2004066944A3 (en) | Products for treating and preventing chronic diseases: eliminating the autoimmune triggers that underly chronic disease | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
| ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
| Bakhshandeh et al. | Mutational spectrum and clinical symptoms of Iranian patients with Charcot-Marie-Tooth disease: a study of 23 patients | |
| NO20074562L (no) | Fremgangsmater for behandling av Parkinsons sykdom |